Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8771170rdf:typepubmed:Citationlld:pubmed
pubmed-article:8771170lifeskim:mentionsumls-concept:C0023520lld:lifeskim
pubmed-article:8771170lifeskim:mentionsumls-concept:C0268596lld:lifeskim
pubmed-article:8771170lifeskim:mentionsumls-concept:C0449450lld:lifeskim
pubmed-article:8771170pubmed:issue4lld:pubmed
pubmed-article:8771170pubmed:dateCreated1996-9-24lld:pubmed
pubmed-article:8771170pubmed:abstractTextThe clinical phenotype of multiple acyl-CoA dehydrogenase deficiency in infancy is characterized by recurrent episodes of hypoketotic hypoglycemia and lipid storage myopathy. Brain damage has been described only as a consequence of severe and protracted hypoglycemia. We describe a child who experienced normal physical and psychomotor development until the age of 3 years, who then developed progressive intention tremors, dysarthria, ataxia, and spastic tetraparesis. Episodes of acute metabolic distress were never observed. Magnetic resonance imaging disclosed abnormal signals within the white matter of the brain and cerebellum, suggesting leukodystrophy. Gas chromatography/mass spectrometry analysis revealed abnormally high levels of glutaric acid, dicarboxylic acids, and glycine derivatives in urine. Riboflavin therapy was initiated at 4 years of age, when the patient had already lost control of trunk and head posture. Consistent improvement rapidly occurred after riboflavin supplementation. Glutaric aciduria type II may cause brain damage, in spite of the absence of acute metabolic distress, and should be considered in the differential diagnosis of leukodystrophies.lld:pubmed
pubmed-article:8771170pubmed:languageenglld:pubmed
pubmed-article:8771170pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8771170pubmed:citationSubsetIMlld:pubmed
pubmed-article:8771170pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8771170pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8771170pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8771170pubmed:statusMEDLINElld:pubmed
pubmed-article:8771170pubmed:monthNovlld:pubmed
pubmed-article:8771170pubmed:issn0887-8994lld:pubmed
pubmed-article:8771170pubmed:authorpubmed-author:RimoldiMMlld:pubmed
pubmed-article:8771170pubmed:authorpubmed-author:UzielGGlld:pubmed
pubmed-article:8771170pubmed:authorpubmed-author:GaravagliaBBlld:pubmed
pubmed-article:8771170pubmed:authorpubmed-author:CiceriEElld:pubmed
pubmed-article:8771170pubmed:authorpubmed-author:MoroniIIlld:pubmed
pubmed-article:8771170pubmed:issnTypePrintlld:pubmed
pubmed-article:8771170pubmed:volume13lld:pubmed
pubmed-article:8771170pubmed:ownerNLMlld:pubmed
pubmed-article:8771170pubmed:authorsCompleteYlld:pubmed
pubmed-article:8771170pubmed:pagination333-5lld:pubmed
pubmed-article:8771170pubmed:dateRevised2006-5-23lld:pubmed
pubmed-article:8771170pubmed:meshHeadingpubmed-meshheading:8771170-...lld:pubmed
pubmed-article:8771170pubmed:meshHeadingpubmed-meshheading:8771170-...lld:pubmed
pubmed-article:8771170pubmed:meshHeadingpubmed-meshheading:8771170-...lld:pubmed
pubmed-article:8771170pubmed:meshHeadingpubmed-meshheading:8771170-...lld:pubmed
pubmed-article:8771170pubmed:meshHeadingpubmed-meshheading:8771170-...lld:pubmed
pubmed-article:8771170pubmed:meshHeadingpubmed-meshheading:8771170-...lld:pubmed
pubmed-article:8771170pubmed:meshHeadingpubmed-meshheading:8771170-...lld:pubmed
pubmed-article:8771170pubmed:meshHeadingpubmed-meshheading:8771170-...lld:pubmed
pubmed-article:8771170pubmed:year1995lld:pubmed
pubmed-article:8771170pubmed:articleTitleRiboflavin-responsive glutaric aciduria type II presenting as a leukodystrophy.lld:pubmed
pubmed-article:8771170pubmed:affiliationDepartment of Child Neurology, Istituto Neurologico C. Besta, Milan, Italy.lld:pubmed
pubmed-article:8771170pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8771170pubmed:publicationTypeCase Reportslld:pubmed